Background: Over-production of reactive oxygen species (ROS) and resulting oxidative stress contribute to retinal damage in vascular diseases that include diabetic retinopathy, retinopathy of prematurity and major retinal vessel occlusions. NADPH oxidase (Nox) proteins are professional ROSgenerating enzymes, and therapeutic targeting in these diseases has strong appeal. Pharmacological inhibition of Nox4 reduces the severity of experimental retinal vasculopathy. We investigated the potential application of this drug approach in humans.
Methods: Differential Nox enzyme expression was studied by real-time-quantitative polymerase chain reaction in primary human retinal endothelial cell isolates and a characterized human retinal endothelial cell line. Oxidative stress was triggered chemically in endothelial cells, by treatment with dimethyloxalylglycine (DMOG; 100 μM); Nox4 and vascular endothelial growth factor (VEGFA) transcript were measured; and production of ROS was detected by 2 0 ,7 0 -dichlorofluorescein. DMOG-stimulated endothelial cells were treated with two Nox1/Nox4 inhibitors, GKT136901 and GKT137831; cell growth was monitored by DNA quantification, in addition to VEGFA transcript and ROS production.
Results: Nox4 (isoform Nox4A) was the predominant Nox enzyme expressed by human retinal endothelial cells. Treatment with DMOG significantly increased endothelial cell expression of Nox4 over 72 h, accompanied by ROS production and increased VEGFA expression. Treatment with GKT136901 or GKT137831 significantly reduced DMOG-induced ROS production and VEGFA expression by endothelial cells, and the inhibitory effect of DMOG on cell growth.
Conclusions:
Our findings in experiments on activated human retinal endothelial cells provide translational corroboration of studies in experimental models of retinal vasculopathy and support the therapeutic application of Nox4 inhibition by GKT136901 and GKT137831 in patients with retinal vascular diseases.
INTRODUCTION
Retinal vascular endothelial cell dysfunction and loss are key elements in the pathology that characterizes diabetic retinopathy, retinopathy of prematurity and major retinal vessel occlusions. [1] [2] [3] Accordingly, there is considerable interest in the therapeutic application of biological drugs that limit endothelial cell damage in these retinal vasculopathies. [4] [5] [6] [7] [8] Multiple molecular changes are observed in the diseased retinal microvasculature; changes include the over-production of reactive oxygen species (ROS), and the resulting oxidative stress both contributes to and perpetuates the vascular disease. [1] [2] [3] High levels of ROS are associated with upregulation of vascular endothelial growth factor (VEGF), which is a master regulator of retinal vascular leakage and neovascularization. Thus, the first biological drugs to be applied successfully to the treatment of retinal vasculopathy block the action of VEGF. [8] [9] [10] Other biologically targeted pharmaceuticals are at various stages in the development pipeline, including drugs that directly target the production of ROS.
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ROS include radicals and non-radicals: superoxide, hydrogen peroxide, hydroxyl radical, peroxynitrite and hypochlorous acid. These molecules act deleteriously through the modification of wide range macromolecules, but they also play physiological roles in cell signalling and have beneficial anti-microbial activity. 12, 13 The NADPH oxidase (Nox) family of proteins have been termed 'professional ROS-generating enzymes' in recognition of enzymatic activity dedicated to the production of ROS. 12 The family includes seven enzymes, which vary in structure, regulation, product and tissue distribution: Nox1 to Nox5, and dual oxidases (Duox), Duox1 and Duox2. One member -Nox4 -exists as two major isoforms, Nox4A and Nox4B.
14 Given the significant role of the Nox family members in the production of ROS, therapeutic targeting of these enzymes in retinal vasculopathy has strong appeal.
Independent studies evaluating the expression of the five Nox enzymes, Nox1 through Nox5, in the same commercially sourced human retinal endothelial cells, have identified Nox4 as the predominant isoform in this cell population. 15, 16 Consistently, selective Nox blockade with a Nox1/Nox4 inhibitor reduces the production of ROS and the severity of neovascularization in rat pups exposed to hyperoxia. 17, 18 We sought to extend the potential application of this drug approach to the human. We first examined the expression of all seven Nox family enzymes in retinal endothelial cell isolates from multiple human donors, as well as a characterized human retinal endothelial cell line. We then evaluated the effect of two selective Nox1/Nox4 inhibitors on human retinal endothelial cell production of ROS, expression of VEGFA and growth. Oxidative stress was triggered chemically in these studies, by treatment with the prolyl-4-hydroxlase inhibitor, dimethyloxalylglycine (DMOG).
METHODS

Chemicals and drugs
DMOG was purchased from Sigma-Aldrich (St. Louis, MO, USA) and used at a concentration of 100 μM, which was titrated in pilot studies to reliably induce the production of ROS. Two pyrazolopyridine dione drugs (i.e. GKT136901 and GKT137831) were provided by Genkyotex SA (Geneva, Switzerland). These drugs are well-characterized dual inhibitors of both Nox1 and Nox4 proteins, and they were identified in high-throughput drug screens that involved cell-free assays of ROS production in human Nox4 membranes. [19] [20] [21] Drug design, synthesis and optimization have been reported by the pharmaceutical manufacturer. 22, 23 5-(and-6)-chloromethyl-2 0 ,7 0 -dichlorodihydro-fluorescein diacetate, acetyl ester (CM-H 2 DCFDA) and CyQUANT NF dye reagent were purchased from Thermo Fisher ScientificMolecular Probes (Eugene, OR, USA).
Endothelial cell isolation and culture
Endothelial cells were isolated from human retina, as we have previously described in detail. 24 In summary, paired retinae were digested with 0.25-1 mg/mL type II collagenase (ThermoFisher Scientific-GIBCO, Grand Island, NY, USA), and cultured at 37 C with 5% CO 2 in air, in MCDB-131 medium (SigmaAldrich) supplemented with 2% fetal bovine serum (FBS) (HyClone-GE Healthcare Life Sciences, Logan, UT, USA) and endothelial growth factors (EGM-2 SingleQuots supplement; Clonetics-Lonza, Walkersville, MD, USA). The FBS, hydrocortisone and gentamicin were omitted from the EGM-2 SingleQuots supplement. After 8-10 days, retinal endothelial cells were purified using magnetic Dynabeads (ThermoFisher Scientific-Invitrogen Dynal, Oslo, Norway) coated with mouse anti-human CD31 antibody (BD Biosciences-Pharmingen, San Diego, CA, USA), and grown in modified MCDB-131 medium with 10% FBS. Retinal endothelial cells used in the experiments involving treatment with DMOG were previously transduced with the mouse recombinant amphotropic retrovirus, LXSN16E6E7, 25 to provide the needed numbers of cells for those studies. This cell line retains an endothelial phenotype, as we have previously reported. 24 The use of human cadaver donor eyes from the Eye Bank of South Australia (Adelaide, Australia), as a source of primary human retinal endothelial cell isolates for these studies, was approved by the Southern Adelaide Clinical Human Research Ethics Committee. Human cadaver eye donors ranged from 35 to 59 years at death, and time from death to processing of the retina averaged 17 h.
RNA isolation and reverse transcription
Cells were treated with Buffer RLT (Qiagen, Hilden, Germany) or Lysis Solution (Sigma-Aldrich) with β-mercaptoethanol (Sigma-Aldrich), and total RNA was extracted using the RNeasy mini kit (Qiagen) or GenElute Mammalian Total RNA Miniprep Kit 
Real-time quantitative polymerase chain reaction
Quantitative real-time PCR was performed on the CFX Connect Real-Time PCR Detection System (BioRad) using 2 μL of cDNA, 4 μL of iQ SYBRGreen Supermix, 1.5 μL each of 20 uM forward and reverse primers (Table 1) C between 70 and 95 C, to confirm that a single PCR product was produced. For the qPCR study of Nox isoform expression, PCR products were verified on 3% agarose gel with SYBR Safe DNA Gel Stain (Thermo Fisher Scientific-Invitrogen, Carlsbad, CA, USA).
ROS detection assay
Human retinal endothelial cells were seeded for confluence in wells of black-wall and transparentbottom 96-well microplates (Corning, Kennebunk, ME, USA) in modified MCDB-131 medium with 10% FBS at 37 C with 5% CO 2 in air. On the following day, the medium was replaced with fresh medium that either contained or did not contain DMOG. In some experiments, the cells were also treated with 100 nM GKT136901 or GKT137831. Medium and supplements were changed every 24 h for experiments that ran over 24 h. At predetermined time intervals, the assay was stopped by staining cells with 10 μM CM-H 2 DCFDA, freshly diluted in EBM Basal Medium Phenol Red Free (Clonetics-Lonza) with 10% FBS for 15 minutes at 37 C in the dark. The CM-H 2 DCFDA was replaced with modified EBM medium ahead of reading on a fluorescence microplate reader (VICTOR X3, PerkinElmer, Singapore) with excitation and emission filters of 485 and 535 nm, respectively. In some experiments, wells were also photographed on the EVOS FL Cell Imaging System (Thermo Fisher Scientific-Invitrogen) at 10-times magnification.
Endothelial cell growth assay
Cells were plated and treated as described for the ROS detection assay. After 72 h, cell growth was stopped by staining cells with CyQUANT NF dye reagent, freshly diluted in Hank's balanced salt solution for 1 h at 37 C in the dark. Subsequently, the CyQUANT NF dye reagent was replaced with phosphate buffered saline, and the wells were read on a fluorescence microplate reader with excitation and emission filters of 485 and 535 nm, respectively.
Statistical methods
Data for test and control conditions were compared by two-tailed Student's t-tests for two-condition comparisons and one-way analysis of variance tests with post-hoc Tukey's testing for multiple-condition comparisons, using CFX Manager v3.1 (Bio-Rad) or GraphPad Prism v6.04 (GraphPad Software, La Jolla, CA, USA). In all analyses, a significant difference between conditions was defined as one yielding a P-value less than 0.05.
RESULTS
The pattern of expression of up to five Nox enzymes -Nox1, Nox2, Nox3, Nox4 and Nox5 -in a commercially available human retinal endothelial cell isolate has been reported by two independent groups. 15, 16 Individual humans may demonstrate considerable differences in gene expression, and thus expression of the complete family of Nox enzymes, including Duox1 and Duox2, plus Nox4A and Nox4B isoforms, was investigated by RT-qPCR in human retinal endothelial cells separately isolated from five human donor eyes. Consistently across the five primary endothelial cell isolates, Nox4 was the predominantly expressed enzyme, with other enzymes expressed at negligible or relatively low levels (Fig. 1a,b) . Of the two Nox4 isoforms, Nox4A had approximately 10-fold higher expression than Nox4B. The same pattern of enzyme expression seen in the primary endothelial cell isolates was also measured in a characterized human retinal endothelial cell line (Fig. 1a) , which therefore was used for subsequent experiments.
Human retinal endothelial cells were stimulated with DMOG for up to 72 h, and expression of Nox4 and angiogenic target, VEGFA, were measured by RT-qPCR. Cellular expression of VEGFA was determined as transcript, not protein, because MCDB-131 medium is supplemented with human recombinant VEGFA, which would confound the results of a protein assay. Production of ROS was measured in parallel, using CM-H 2 DCFDA as an indicator: intracellular oxidation of the processed molecule yields a fluorescent product. Expression of Nox4 increased significantly in DMOG-exposed endothelial cells in comparison to expression in control cells treated with medium alone at 24, 48 and 72 h of stimulation (Fig. 2a ). Imaging after CM-H 2 DCFDA treatment demonstrated increased fluorescence of cell monolayers exposed to DMOG versus control monolayers across all time points, but most obviously at 48 and 72 h (Fig. 2b) . Measurements of cell fluorescence by plate reader consistently indicated increased levels in DMOG-exposed cells, which were significantly higher than measurements from control cells at 48 and 72 h (Fig. 2c) . The DMOG-stimulated cells also significantly increased the expression of VEGFA from baseline levels at 24, 48 and 72 h (Fig. 2d) . These results indicate DMOG induces production of ROS and VEGFA in human retinal endothelial cells.
There is no drug currently prescribed in humans that inhibits Nox4 alone. However, the pyrazolopyridine dione drugs, GKT136901 and GKT137831, are selective Nox1/Nox4 inhibitors. 21 Having demonstrated that Nox4 was expressed by human retinal endothelial cells and that increased expression, induced by DMOG, was associated with the production of ROS and VEGFA by the cells, we investigated the effect of the Nox1/Nox4 inhibitors on these Nox4-related activities. Similar effects were observed following treatment with GKT136901 or GKT137831: both drugs significantly reduced production of ROS (Fig. 3a,b) and expression of VEGFA (Fig. 3c,d ) by DMOG-stimulated human retinal endothelial cells. In an independent experiment, neither drug altered the constitutive level of VEGFA expression (Fig. S1, Supporting  Information) .
A key feature of retinal vasculopathy is loss of endothelial cells from the retinal vasculature. 1, 26 Therefore, we also examined the effect of the Nox1/ Nox4 inhibitors on retinal endothelial cell growth, using an assay in which final cell number was estimated from binding of fluorescent dye to cellular DNA. In this assay, 72-h treatment with DMOG significantly reduced fluorescence of retinal endothelial cell monolayers from baseline, indicating reduced cell proliferation (Fig. 4a,b) . Treatment with GKT136901 or GKT137831 did not impact cell growth in comparison to that of control cell monolayers treated with medium alone, but resulted in significant reversal of the inhibitory effect of DMOG. These results indicate that selective Nox4 inhibition with GKT136901 or GKT137831 limits the generation of ROS and VEGFA, and promotes normal cell growth under conditions of oxidative stress.
DISCUSSION
The seven members of the Nox family of enzymes are differentially expressed by different cell populations in different body tissues. We have found Nox4 -and its A isoform in particular -to be the predominantly expressed enzyme in human retinal endothelial cell isolates from five different human donors, as well as a human retinal endothelial cell line. This observation confirms and extends previous investigations. Studying human retinal endothelial cells from the same commercial source (Cell Systems, Kirkland, WA, USA), Li et al. 15 identified Nox4 as predominant over Nox1 and Nox2, and Wang et al.
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identified Nox4 as predominant over Nox1, Nox2, Nox3 and Nox5. We have highlighted differences in retinal endothelial cell gene expression between individuals. 27 For the Nox enzymes, however, we saw a remarkably similar pattern of expression across multiple cell isolates. Nox4 is also the predominant Nox enzyme expressed in other human vascular endothelial populations, including aortic, pulmonary arterial, umbilical venous and coronary arterial endothelial cells. [28] [29] [30] [31] As was comprehensively summarized in the recent review by Wang and Hartnett, 32 Nox4 participates in endothelial homeostatic and pathological processes; the nature of this involvement relates to multiple variables that include tissue location and timing, as well as the process in question. Thus, in comparison to control animals, Nox4 gene-deleted mice or mice treated with Nox4 inhibitor demonstrate reduced capillary growth in the gastrocnemius muscle, in response to running exercise on a wheel or treadmill 33 ; poor recovery of capillary density and blood flow in the leg following femoral artery ligation 34 ; and less aggressive pulmonary neovascularization in experimental pulmonary hypertension. 35 In the mouse eye, Nox4 deficiency does not impact the normal radial outgrowth of retinal blood vessels from the optic nerve in the developing retina. 33 However, Nox4 has been identified as a mediator of mouse and rat vascular retinopathies, in studies conducted by several independent groups. 15, 16, 33, 36 Our work -involving exposure of human retinal endothelial cells to DMOG -is more relevant to retinal pathology than homeostasis. Within 24 h of treatment with DMOG, and across the 72-h duration of the exposure, endothelial cells significantly increased their expression of Nox4. Upregulation of the oxidase was associated with augmented production of ROS and expression of VEGFA, which are key players in the development of retinal vasculopathy. Diabetic leptin receptor db homozygous mice experience increased expression of Nox4 in the retina, 15, 37 and intravitreal delivery of a Nox4-targeted small interfering RNA reduces retinal VEGFA and retinal vascular leakage, in parallel with reduced Nox4 expression. 15 Retinal Nox4 expression is also increased in the mouse model of oxygen-induced retinopathy, 16, 36 and Nox4 blockade through genetic deletion or RNA interference reduces pathological retinal neovascularization in this model. 33, 36 Given constitutive and inducible expression of Nox4 in human retinal endothelial cells, plus the protective effect of Nox4 genetic deletion or RNA interference in experimental retinal vascular disease, there is clear potential for Nox4 blockade as a treatment of retinal vasculopathies, including diabetic retinopathy. GKT136901 and GKT137831 are pyrazolopyridine diones that target Nox1 and Nox4. 21 Studies of these two drugs in mouse models of diabetic nephropathy have showed effects that include preservation of renal architecture and reduced albuminuria. 38, 39 GKT137831 has already been administered to in human subjects: the drug was well tolerated by patients in one short phase II trial for diabetic nephropathy, and a 48-week phase II study in patients with type I diabetes mellitus and early nephropathy was recently launched in Australia. In two reports, WilkinsonBerka et al. 17, 18 have described beneficial effects of GKT137831 in rat oxygen-induced retinopathy, including reduced retinal vascular leakage, avascularity and neovascularization.
Our experiments indicate both GKT136901 and GKT137831 reduce DMOG-induced production of ROS and expression of VEGFA by human retinal endothelial cells. A central early event in retinal vasculopathy is endothelial cell loss, 26, 40 and importantly, GKT136901 and GKT137831 also significantly reverse the negative effect of DMOG on human retinal endothelial cell growth. The DMOGassociated reduction in cell growth likely reflects a negative effect on cell cycle progression. Hypoxiainducible factor (HIF)-1α induces cell cycle arrest. 41 In keeping with the HIF-1α-stabilizing activity of DMOG, we have measured reduced expression of cell cycle promoter, cyclin D1, in human retinal endothelial cells treated for 72 h with DMOG; consistently, we have observed that GKT136901 and GKT137831 prevent this reduction in cyclin D1 expression (data not shown). However, given that Nox1/Nox4 inhibition only partially reverses the negative effect of DMOG on cell growth, signalling pathways other than Nox4-mediated ROS production may contribute to the growth inhibition associated with DMOG treatment. Alternatively, or additionally, technical factors such as the concentration or timing of application of the Nox1/Nox4 inhibitors also may impact the degree of reversal.
In summary, our studies in human retinal endothelial cells provide a translational corroboration of studies conducted in rodents that support the therapeutic potential for targeted Nox inhibition with GKT137831 in patients with retinal vasculopathy. Nox4 is the predominant Nox enzyme expressed by human retinal endothelial cells, and inhibition of enzyme induction limits production of ROS by these cells and promotes their growth. Our work also suggests that possibility of targeting Nox4 in other retinal diseases that involve oxidative stress in the retinal endothelium, including proliferative vitreoretinopathy and posterior uveitis. 42, 43 
